After resisting a push to the auction block, Acorda preps for a sale and shares shoot up — report
Over the last 8 months Acorda $ACOR has had to lay off staffers in a painful restructuring as it reacted to the likely loss of patent protection for its sole franchise drug, watched a critical drug application get kicked back as inadequate, scrapped a top pipeline therapy following the death of a slate of patients and adopted a poison pill defense as a key investor pushed for a sale.
But now company CEO Ron Cohen may be having second thoughts about the advisability of a sale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
